(de-news.net) – German Health Minister Nina Warken (CDU) has rejected pharmaceutical industry demands for exemptions from planned healthcare savings measures, arguing that all sectors must contribute to reform efforts. While acknowledging economic pressures on drugmakers, she maintained that Germany remains an attractive pharmaceutical market and dismissed warnings of negative consequences for patients or innovation.
The pharmaceutical industry’s requests for amendments to the contribution stabilization regulation have been rejected by the German Health Minister. In defending the government’s position, Warken argued that the burden of the proposed reform should be shared across all affected sectors and maintained that excluding pharmaceutical manufacturers from the planned cost-saving measures had not been considered as a viable option. Her stance reflects the broader principle that every stakeholder within the healthcare system should contribute to efforts aimed at maintaining financial sustainability.
Her comments were made in response to increasingly sharp criticism from the pharmaceutical sector regarding the proposed measures. Despite indications from U.S.-based Eli Lilly and Germany’s Boehringer Ingelheim that they could reconsider, postpone, or scale back planned investments, Warken remained firm in her assessment of the reform package. She maintained that the government’s proposal represented a balanced and proportionate approach that sought to reconcile competing interests within the healthcare system. In doing so, she gave no indication that the federal government intended to revise its overall course in response to industry pressure.
Warken rejects windfall claims, highlights competitive pharma environment
At the same time, the Minister acknowledged that many pharmaceutical companies are currently operating under significant economic pressures. Nevertheless, she emphasized that the legislation was not designed to create additional revenue opportunities for the industry. Rather, the reform is being pursued within the broader context of healthcare financing. Warken stressed that Germany continues to offer substantial advantages as a location for pharmaceutical activity, citing the reimbursement framework provided by statutory health insurance, favorable conditions for scientific research, and extensive opportunities for conducting clinical trials. These factors, she suggested, continue to support the country’s attractiveness for both domestic and international pharmaceutical companies. Simultaneously, she noted that the Federal Government intends to continue developing its pharmaceutical strategy, including reviewing industry proposals aimed at improving the predictability of investment planning and further refining the framework conditions under which the sector operates.
Warken also dismissed concerns that the reform could have negative consequences for patients. Addressing warnings that changes to the regulatory framework might adversely affect access to medicines or healthcare outcomes, she argued that statutory health insurance remains a highly valuable partner for pharmaceutical manufacturers. Although its financial resources are necessarily limited, the system continues to provide the industry with a large, stable, and dependable market for pharmaceutical products, thereby offering a degree of commercial certainty that remains significant for manufacturers.
The Minister further argued that Germany would continue to serve as an attractive launch market for innovative medicines. In support of this position, she pointed out that pharmaceutical companies retain the ability to set introductory prices freely during the first six months following a product’s entry into the market. According to Warken, this regulatory feature contributes to the country’s appeal for the introduction of new therapies. She additionally maintained that Germany offers the fastest access to newly developed medicines within Europe. In her view, this combination of rapid market access and favorable launch conditions demonstrates Germany’s continuing importance as a key strategic market for the global pharmaceutical industry and reinforces its status as a significant location for pharmaceutical innovation and commercialization.
Audio: TTSFree
